Regeneron (REGN) Announces IDMC Finds Clear Efficacy for REGEN-COV in Phase 3 COVID-19 Outpatient Outcomes Trial
Go back to Regeneron (REGN) Announces IDMC Finds Clear Efficacy for REGEN-COV in Phase 3 COVID-19 Outpatient Outcomes TrialRegeneron (NASDAQ: REGN) | Delayed: 892.21 -1.78 (0.2%) | |||||
---|---|---|---|---|---|---|
Previous Close | $893.99 | 52 Week High | $592.36 | |||
Open | $913.97 | 52 Week Low | $325.35 | |||
Day High | $920.73 | P/E | 234.18 | |||
Day Low | $891.67 | EPS | $3.81 | |||
Volume | 153,355 |